Table 3.
Univariate and multivariate Cox proportional hazards analysis of factors influencing 5-year overall survival for patients who underwent FOLFOX/CapeOX chemotherapy
| Variables | Univariate analysis | Multivariate analysis* | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Gender | 0.092 | |||||
| Male | 1 | |||||
| Female | 0.845 | 0.695–1.028 | ||||
| Age at diagnosis, years | 0.003 | 0.007 | ||||
| 66–70 | 1 | 1 | ||||
| 71–75 | 1.122 | 0.872–1.443 | 1.149 | 0.888–1.486 | ||
| 76–80 | 1.286 | 0.994–1.665 | 1.293 | 0.991–1.688 | ||
| > 80 | 1.812 | 1.305–2.517 | 1.816 | 1.285–2.566 | ||
| Race | 0.206 | |||||
| White | 1 | |||||
| Black | 1.028 | 0.719–1.469 | ||||
| Asian | 1.156 | 0.677–1.972 | ||||
| Other | 0.502 | 0.259–0.973 | ||||
| Marital status | 0.167 | |||||
| Single+Separated | 1 | |||||
| Married | 1.036 | 0.696–1.543 | ||||
| Divorced+Widowed | 1.318 | 0.869–1.999 | ||||
| Other | 1.066 | 0.540–2.104 | ||||
| Residence location | 0.329 | |||||
| Big Metro | 1 | |||||
| Metro or Urban | 1.071 | 0.865–1.327 | ||||
| Less Urban or Rural | 1.252 | 0.929–1.686 | ||||
| Median household income | 0.007 | 0.497 | ||||
| 1st quartile | 1 | 1 | ||||
| 2nd quartile | 0.962 | 0.733–1.261 | 1.021 | 0.755–1.380 | ||
| 3rd quartile | 0.745 | 0.561–0.989 | 0.814 | 0.575–1.152 | ||
| 4th quartile | 0.620 | 0.465–0.826 | 0.792 | 0.529–1.186 | ||
| Unknown | 0.800 | 0.496–1.291 | 0.947 | 0.514–1.743 | ||
| Level of education | 0.006 | 0.263 | ||||
| 1st quartile | 1 | 1 | ||||
| 2nd quartile | 1.524 | 1.117–2.079 | 1.371 | 0.979–1.920 | ||
| 3rd quartile | 1.552 | 1.147–2.100 | 1.379 | 0.960–1.982 | ||
| 4th quartile | 1.744 | 1.298–2.343 | 1.289 | 0.854–1.947 | ||
| Unknown | 1.417 | 0.863–2.327 | N/Aa | N/Aa | ||
| Year of diagnosis | 0.398 | |||||
| 2001–2004 | 1 | |||||
| 2005–2008 | 0. 897 | 0.697–1.154 | ||||
| Primary tumor site | 0.150 | |||||
| right-sided colon | 1 | |||||
| left-sided colon | 0.878 | 0.711–1.084 | ||||
| unknown | 1.602 | 0.824–3.114 | ||||
| Histologic grade | < 0.001 | 0.022 | ||||
| Well | 1 | 1 | ||||
| Moderate | 1.170 | 0.724–1.892 | 1.015 | 0.623–1.653 | ||
| Poor+Undifferentiated | 1.973 | 1.211–3.215 | 1.407 | 0.856–2.315 | ||
| Unknown | 1.376 | 0.598–3.165 | 0.987 | 0.422–2.309 | ||
| Histologic type | 0.008 | 0.148 | ||||
| Adenocarcinoma | 1 | 1 | ||||
| Mucinous carcinoma | 1.491 | 1.146–1.940 | 1.306 | 0.997–1.712 | ||
| Signet-ring cell carcinoma | 1.467 | 0.728–2.959 | 1.147 | 0.556–2.366 | ||
| pT category | < 0.001 | < 0.001 | ||||
| pT1 | 1 | 1 | ||||
| pT2 | 1.374 | 0.499–3.780 | 1.472 | 0.531–4.080 | ||
| pT3 | 3.645 | 1.506–8.823 | 2.730 | 1.118–6.667 | ||
| pT4a | 6.221 | 2.494–15.521 | 5.077 | 2.014–12.801 | ||
| pT4b | 7.165 | 2.766–18.559 | 4.350 | 1.656–11.424 | ||
| pN category | < 0.001 | < 0.001 | ||||
| pN1a | 1 | 1 | ||||
| pN1b | 1.581 | 1.172–2.132 | 1.475 | 1.090–1.996 | ||
| pN2a | 2.301 | 1.691–3.132 | 1.970 | 1.440–2.696 | ||
| pN2b | 4.310 | 3.195–5.814 | 3.408 | 2.497–4.650 | ||
| Preoperative intestinal obstruction | < 0.001 | 0.055 | ||||
| No | 1 | 1 | ||||
| Yes | 1.680 | 1.340–2.106 | 1.258 | 0.995–1.590 | ||
| Preoperative intestinal perforation | 0. 165 | |||||
| No | 1 | |||||
| Yes | 1.770 | 0.790–3.966 | ||||
| HCC risk score | < 0.001 | < 0.001 | ||||
| 1st quartile | 1 | 1 | ||||
| 2nd quartile | 0.936 | 0.683–1.283 | 1.129 | 0.816–1.561 | ||
| 3rd quartile | 1.033 | 0.754–1.415 | 1.273 | 0.918–1.765 | ||
| 4th quartile | 1.994 | 1.469–2.705 | 2.197 | 1.592–3.033 | ||
| Number of examined lymph node | 0.382 | |||||
| ≥ 12 | 1 | |||||
| < 12 | 0.906 | 0.727–1.130 | ||||
| Postoperative radiotherapy | 0.055 | |||||
| No | 1 | |||||
| Yes | 1.850 | 0.988–3.467 | ||||
| Timing to AC | < 0.001 | < 0.001 | ||||
| ≤ 4 weeks | 1 | 1 | ||||
| 5–8 weeks | 1.028 | 0.635–1.663 | 1.009 | 0.619–1.644 | 0.971 | |
| 9–12 weeks | 1.665 | 1.012–2.739 | 1.640 | 0.990–2.717 | 0.055 | |
| 13–16 weeks | 1.671 | 0.935–2.988 | 1.422 | 0.788–2.566 | 0.243 | |
| ≥ 17 weeks | 3.144 | 1.731–5.710 | 2.482 | 1.354–4.549 | 0.003 | |
Abbreviation FOLFOX/CapeOX 5-FU/capecitabine plus oxaliplatin, HR Hazard ratio, CI Confidence interval, HCC Hierarchical Condition Categories, AC Adjuvant chemotherapy
*Only variables with a p < 0.05 in the univariate analysis were included in the multivariate analysis
aunavailable because of colinearity with the variable of Median household income